296P Efficiency of intermittent androgen blockade in patients with advanced prostate cancer

Abstract

Background One of the methods to prevent the development of hormone-resistant prostate cancer (PC) is intermittent androgen blockade (IAB). The concept of IAB is in a temporary androgen blockade, in which stem tumor cells are partially preserved. When a certain response is achieved, antiandrogen therapy is stopped to allow the growth of new clones of androgen-sensible cancer cells. Then treatment is resumed. The mechanism of this method is based on the activity of the remaining stem tumor cells, which cause the growth of androgen-dependent colony, receptive to re-hormonal treatment. Methods The study included 235 patients with advanced prostate cancer who were treated at the City Cancer Center, Tashkent city. Patients were divided into 2 groups: group 1(n = 49) - patients underwent surgical castration; group 2(n = 186) - patients received combined hormone therapy. All patients from group 2 were treated in the mode of intermittent therapy with - LHRH agonist - goserelin acetate 3.6 mg in the form of a depot injection 1 time per month and the injection form of cyproterone acetate 300 mg 2 times a month in combination with bisphosphonates. Results The study included 235 patients with advanced prostate adenocarcinoma. In group1 (n=49),wherepatientsreceivedorchiectomy,theaverageageofpatientswas 77.0861.12years.In18patients(36.766.88%) theprevalenceoftumorprocesswas T2NxMx,26patients(53.167.12%)-T3NxMx,5patients(10.264.32)-T3NxMx.19 patients (38.7 6 6.96%) were detected to have skeletal bone metastases, retroperitoneal and iliac lymph nodes. Conclusions The results of our research confirm the effectiveness of hormone therapy IAB in comparison with the traditional method of surgical castration. Our certain methods of selecting the optimal mode of hormonal therapy, depending on prognostic factors has led to improved health outcomes and quality of life of patients with advanced prostate cancer. Herewith, determination of the period of the second cycle start of hormone therapy is decided individually for each patient based on the PSA level before treatment and on the extent of tumor spread, dynamics of clinical symptoms, tolerance to androgen blockade. Legal entity responsible for the study Yusupov Sherali Khasanovich Funding Tashkent city oncology dispanser Disclosure All authors have declared no conflicts of interest.